The combination strategies of KRAS G12C inhibitors and YAP/TAZ inhibition exert synergistic effects in multiple KRAS G12C–mutant cancer cell lines that exhibit intrinsic or acquired resistance to KRAS G12C inhibitors. This evidence concerns the gene KRAS and cancer.